Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds – Medical Marijuana Program Connection

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has identified three novel compounds from its EVM301 Series with the potential to offer a first-in-class approach to address difficult-to-treat disorders by promoting neuroplasticity without inducing h

Source link

• SEO Powered Content & PR Distribution. Get Amplified Today.
• PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
• PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
• PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
• PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
• Source: https://mmpconnect.com/enveric-biosciences-selects-development-candidates-from-evm301-series-based-on-potential-to-minimize-or-eliminate-the-hallucinogenic-effect-of-psychedelic-derived-compounds/?utm_source=rss&utm_medium=rss&utm_campaign=enveric-biosciences-selects-development-candidates-from-evm301-series-based-on-potential-to-minimize-or-eliminate-the-hallucinogenic-effect-of-psychedelic-derived-compounds